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INTRODUCTION
Broad spectrum β-Lactamase producing organisms are a growing world wide problem. It was first observed in 1983 in isolates of Klebsiella pneumonia. The extended spectrum β-Lactamase (ESBL) producing strains have variable susceptibility rates for flouroquinolones, aminoglycosides and fourth generation cephalosporins (2) . World wide data shows that there is an increasing resistance among UTI pathogens to conventional drugs. Resistance has emerged ever to newer, more potent antimicrobial agents (3) . Anti-microbial resistance surveillance is necessary to determine the size of problem and to guide empirical selection of anti-microbial agents for treating infected patients. In gram-ve pathogens, β-Lactamase production remains the most important contributing factor to β-Lactamase resistance (4) . β-Lactamases are bacterial enzymes that inactivate β-Lactam antibiotics by hydrolysis which results in ineffective compounds. One group of β-Lactamases; Extended spectrum β-Lactamases (ESBLs) have the ability to hydrolyse and cause resistance to various types of the newer β-Lactam antibiotics including the expanded-spectrum (or third-generation) cephalosporins (e.g: cefotaxime, ceftriaxone & ceftazidime) and monobactams (e.g: aztreonam) but not the cephamycins (e.g: cefoxitin and cefotetan and carbapenems (e.g: imipenem, meropenem and ertapenem) (5) . Organisms that produce ESBLs remain an important reason for the rapid failure with cephalosporins and have serious consequences for infection control (6) . So The clinical microbiology laboratories that detect and report ESBL producing organisms is therefore important. Most ESBLs can be divided into three groups: TEM, SHV and CTX-M types.
Klebseilla pneumonia and Escherichia coli remain the major ESBL-producing organisms isolated world wide, but these enzymes have also been identified in several other members of the Enterobacteriacae family and in certain non-fermenters 
MATERIAL & METHODS
Out of 250 clinical isolates, ceftazidime or cefotaxime resistant Enterobacter species, Klebseilla species, E.coli, Acinetobacter baumanii and Pseudomonas aeruginosa isolates were selected for the molecular study. All these isolates were obtained from Tanta University Hospital from July 2013 to April 2014. These 250 isolates were obtained from various clinical specimens : Samples were skin swabs either by touching or squeezing from cases of cellulitis (3), impetigo contagiosum (non bullous) (20) and sycosis (8) from Dermatology and Venereology Department, Faculty of Medicine, Tanta University, (46) blood specimens from bacteraemic patients, (28) pus from infected wounds, (58) from endotracheal secretions, (64) urine from cases of acute pyelonephritis and cystitis and (23) The organism to be tested was spread onto Mueller-Hinton agar plate surface. The antibiotic discs used were Ceftriaxone (30mg), Cefotaxime (30mg), Ceftazidime (30mg), and Amoxycillin Clavulanic acid (20/10mg). The three antibiotics were placed at distances of 30mm (edge to edge) from the Amoxycillin/ Clavulanic acid disc that was placed in the middle of the plate. After 24-hours incubation, if an enhanced zone of inhibition between either of the Cephalosporin antibiotics and the Amoxycillin/Clavulanic acid disc occurred, the test was considered positive. This indicated synergistic activity with Clavulanic acid and the presences of an ESBL. 
II-Phenotypic confirmatory disc diffusion test (combind disc method)(18)
A ceftazidime (30mg) disc was used alone and in combination with Clavulanic acid (30mg /10mg) for phenotypic confirmation of the presence of ESBLs. A ≥5 mm increase in zone diameter for either of the Cephalosporin discs and their respective Cephalosporin / Clavulanate discs was interpreted as ESBLs producer (Fig.1) .
Fig(2):
Phenotypic confirmatory disc diffusion test using ceftazidime disc 30 mg and ceftazidime/ clavulanate disc 30/10 mg, >5 mm increase in zone diameter for antimicrobial agent tested in combination with clavulanate versus its zone when tested alone = ESBL
Multiplex PCR assay (CTX-Mplex PCR).
To confirm that each primer set was sufficient for the amplification of a subgroup(s) -specific fragment, a monoplex PCR was first performed with each individual primer set using 10 phenotypically and genotypically wellcharacterized CTX-M-type ESBL-producing control strains. The specificity of the primers was then evaluated with the combined primer sets in the multiplex PCR with different PCR cycling parameters. PCR amplification was performed with template DNA prepared from the heat treatment of bacterial suspension (95ºC, 5 min). Five microlitres template DNA was added to a 50 M reaction mixture containing 25 mM Tris HCL, 50 mM KCL, 1.5 mM MgCl2, 0.2mM each d NTP (Qiagen), all primers at various concentrations and 2.5U Taq polymerase (Qiagen). The cycling parameters were as follows: 95ºC for min followed by 30 cycles of 95º C for 1 min. 55ºC for 1 minute and 72ºC for another minute with a final extension at 72ºC for 10 minutes, Four microlitres of the PCR product was mixed with 2ml loading buffer and separated on a 2% agrose gel in TBE buffer. Amplified products were visualized with UV light after staining with ethidium bromide.
Duplex detection of different groups of bla CTX-M carrying isolates by the multiplex PCR was also evaluated by mixing DNA templates from two groups (5µl each).
Specificities of the multiplex PCR
The monoplex PCR amplification with 10 bla CTX-M-carrying control strains exhibited four distinct bands corresponding to the expected size, i.e., 207, 260, 293 and 341 bp (not shown). The specificity of the primers was then evaluated with the combined primer sets in the multiplex PCR. Using 20 pmol for each primer, a specific PCR fragment was obtained for groups 1, 2 and 25/26, and non-specific products were seen. Although the primer set for group 1 showed a lack of similarity with sequences of all the other groups, a faint crossreactive band with group 9 was observed. To optimize the multiplex PCR assay and ensure specificity and reliability, primer sets were mixed in different ratios in multiplex PCR assay and ensure specificity and reliability, primer sets were mixed in different ratios in multiplex PCRs. The best results, which resulted in the loss of non-specific banding from the primer pair for group 1 to group 9 template, were obtained with the following primer concentrations: 10 pmol for CTXM7 and CTXM8, 20pmol for CTXM13, CTXM14, CTXM18 and CTXM19 and 40 pmol for CTXM11 and CTXM12. No products were obtained from control strains that produced SHV-11, SHV-12and TEM-1 (Table 1 and 
RESULTS
Out of 250 isolates only 98 cases were proved to be resistant to the different types of antibiotics by the disc diffusion method according to NCCLS &those were subjected to the multiplex PCR for the detection of CTX-M gene &discrimination between its types &results were as follows: bla CTX-M genes were found in: The occurrence or association of more than one β-lactamase within the same isolate has been reported. The sequence of each bla ctx-m subgroup were aligned with CLUSTAL W and Genedoc. The sequence alignments were generated from 18 strains of group 1 (CTX-M-1,-3, -10,-11 ,-12,-15,-22, -23,-27,-28,-29,-30,-32,-33,-34,-36 ,-37 and -42),9 strains of group 2(CTX-M-2,-4,-5,-6,-7,-20,-31,-35 and Toho -1) and 11 strains of group 9 (CTX-M-9,-13,-14,-16,-17,-18,-19,-21,-24,-38 and Toho -2). The sequences from six strains, three from group 8 (CTX-M-8, CTX-M-40 and CTX-M-41) and three from group 25/26 (CTX-M-25,-26 and -39), were aligned together. They have previously all been classified within group 8 (12) and consequently this study will identify group 8and 25/26 as one group. The group-specific primer sets were designed in the highly conserved region of the alignments.
The derived primer sets were subsequently aligned against all other members of different group sequences in order to reduce the risk of cross-reactivity. A total of four primer sets were identified to amplify an internal region of the bla CTX-M genes from the five groups.
Primer pairs CTXM7 and CTXM8, CTX17 and CTXM18 and CTXM11 and CTXM12 are specific to groups 1,2 and 9,while CTXM19 and CTXM20 amplify both groups 8 and 25/26 .CTXM19 and CTXM20 have 100% sequence similarity with group 25/26 and only one base mismatch in both the 5´ and 3´ ends with group 8. We were not able to test CTXM 19 and 20 with bla CTXM-8 carrying strains as these were not available to us. The amplified multiplex PCR fragments from isolates representing group 1,2,9,8 and 25/26 ranged from 207 to 341 bp (table 2 and figure 2).
DISCUSSION
The increasing incidence of ESBL S among Enterobactericae is a growing worldwide problem. It has become necessary to correctly identify the genes involved in ESBL problem mediated resistance, for the surveillance and epidemiological studies of their transmission in hospitals, therefore, ESBL S producing organisms should be identified quickly so that appropriate antibiotic usage & infection control measures can be implemented.
-Isoelectric focusing analysis is very time consuming and difficult to standardize however, it was used in the early studies of ESBL S
The recent molecular methods of TEM and SHV derivatives identification e.g: PCR -RFLP and ligase chain reaction are usually used to detect a single type of ESBL. -Multiplex PCR plays an important role to screen a large number of clinical isolates producing bla SHV & bla CTX -M type ESBLS. -In India, variant of CTX-M 3 enzyme, designated CTX-M-15 was repotted from six unrelated members of family enterobactericae. Grover et al, in India reported that bla TEM and bla SHV alone or together were present in 88.8% of the klebseilla isolates in their study. Rodriques et al, has reported that 53% of the nosocomial gram -ve were found to be ESBL Several out breaks caused by CTX-M type ESBL S have been reported -In the UK, a recent study identified an epidemic CTX-M-15 producing E.coli with more than 100 communities and in patient isolates involved. CTX-M 9,14 (group 9) and 15 (group1) were found in both community &hospitals in York.
The occurrence or association of more than one β-lactamase within the same isolate has been reported.
In our study, we found bla CTX-M to be predominantly isolated in Ecoli species and Enterobacter species whereas bla CTX-M Amplification produced a band at 542 bp. 
